Get started
CCC

Citius Oncology, Inc.

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Seasonals

CTOR chart


Full chart

Key stats


Market capitalization
‪89.86 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
4.82
Basic EPS (TTM)
0.24 USD
Net income (FY)
‪2.42 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪345.03 K‬
Beta (1Y)
−3.94

About Citius Oncology, Inc.


Sector
Health Technology
CEO
Leonard L. Mazur
Headquarters
Cranford
Founded
2021
FIGI
BBG01163HKY3
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CTOR news



Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CTOR is 1.29 USD — it has increased by 6.81% in the past 24 hours. Watch Citius Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Citius Oncology, Inc. stocks are traded under the ticker CTOR.
CTOR stock has risen by 3.30% compared to the previous week, the month change is a 20.03% rise, over the last year Citius Oncology, Inc. has showed a −88.18% decrease.
CTOR reached its all-time high on Aug 6, 2024 with the price of 49.00 USD, and its all-time low was 0.93 USD and was reached on Oct 10, 2024. View more price dynamics on CTOR chart.
See other stocks reaching their highest and lowest prices.
CTOR stock is 9.72% volatile and has beta coefficient of −3.94. Track Citius Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Citius Oncology, Inc. there?
Today Citius Oncology, Inc. has the market capitalization of ‪17.20 M‬, it has increased by 0.46% over the last week.
Yes, you can track Citius Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
CTOR net income for the last quarter is ‪252.46 K‬ USD, while the quarter before that showed ‪489.83 K‬ USD of net income which accounts for −48.46% change. Track more Citius Oncology, Inc. financial stats to get the full picture.
No, CTOR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CTOR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Citius Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Citius Oncology, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Citius Oncology, Inc. stock shows the neutral signal. See more of Citius Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.